Veradermics Inc (MANE)
Veradermics, Incorporated is a biopharmaceutical company developing therapies for dermatologic and aesthetic conditions. Its pipeline includes VDPHL01, an oral, non-hormonal treatment for pattern hair loss in men and women, along with VDMN, a dissolvable microarray patch platform being developed for immunotherapy of common warts. The company is also advancing VDAA for alopecia areata and VDMC for molluscum contagiosum. More broadly, its work addresses conditions such as androgenetic alopecia, atopic dermatitis, common warts, and molluscum contagiosum across adult and pediatric patient populations. Veradermics serves healthcare providers, clinicians, and the broader medical and research community in dermatology. Founded in 2019, the company is based in New Haven, Connecticut, and its common stock is listed on the NYSE under the symbol MANE.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-MANE
|
$70.17
|
-37.2% Downside
|
Overvalued
|
$161
|
44.1% Upside
|
Undervalued
|
Excellent
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-47.2x
|
11.9x
|
—
|
4.43 B
|
4.276 B
|
0.0%
|
65.1%
|
395.7
|
—
|
80.4%
|
